Developing pharmacological therapies for Alzheimer disease

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer disease (AD) is a chronic, progressive, multifactorial, and heterogeneous neurodegenerative disorder.
• AD presents a significant therapeutic challenge due to its complexity and numerous potential targets.
• Identifying pivotal targets within AD pathogenesis is crucial for effective pharmacological intervention.

Purpose of the Study:

• To identify and evaluate pivotal therapeutic targets for Alzheimer disease.
• To explore the role of tau hyperphosphorylation as a key pathological event in AD.
• To assess strategies for inhibiting abnormal tau phosphorylation for potential AD treatment.

Main Methods:

• Review of AD pathogenesis, focusing on molecular mechanisms of neurofibrillary degeneration.
• Analysis of the role of tau protein, its hyperphosphorylation, and aggregation in AD.
• Evaluation of therapeutic strategies targeting tau kinases (e.g., GSK-3beta, cdk5) and phosphatases (e.g., protein phosphatase-2A).

Main Results:

• Abnormal hyperphosphorylation of tau, rather than aggregation, is identified as the most detrimental step in neurofibrillary degeneration.
• Downregulation of protein phosphatase-2A activity or upregulation of tau kinases contributes to abnormal tau hyperphosphorylation.
• Restoring phosphatase activity or inhibiting specific tau kinases are promising therapeutic avenues.

Conclusions:

• Targeting the pivotal event of abnormal tau hyperphosphorylation offers a promising therapeutic strategy for Alzheimer disease.
• Inhibiting key tau kinases like GSK-3beta and cdk5, or restoring phosphatase activity, are viable approaches for AD treatment development.